JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $230 to $200.
JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $200
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.